→ Belgium’s Ablynx has teed up one of its Nanobodies for osteoarthritis for Merck KGaA. The German company accepted it and will now take it into the clinic, triggering a €15 million milestone payment.
→ JDRF says it will support ViaCyte’s work on a Type 1 diabetes program.
→ Shares of EyeGate Pharmaceuticals $EYEG jumped on the news that it has grabbed a development milestone from Valeant for its pact covering the EyeGate II Delivery System and EGP-437 combination product for post-operative ocular inflammation and pain in ocular surgery patients.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription